No Data
Immuno-Biological Laboratories: Confirmation letter
Immuno-Biological Laboratories: Half Year Report - Term 43 (2024/04/01 - 2025/03/31)
Steady, supported by high US stocks, etc., [individual stock strategy for emerging markets].
[Emerging markets Individual Stock Strategy] Today's emerging markets are expected to show a strong performance based on the positive development in the U.S. stock market on the 11th, with the Dow Jones up 304.14 points (+0.69%) to 44,293.13 points. Buying continued as expectations for regulatory relaxation and growth-oriented policies by the upcoming Trump administration. Small-cap stocks were bought due to rotation, while high-tech stocks were sold off and the Nasdaq temporarily declined. The Dow Jones remained strong throughout the day, reaching record highs consecutively. Today's emerging markets are dominated by buying.
Immuno Biological Labs 1H Net Y71.00M Vs Net Y26.00M
Immuno-Biological Laboratories: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Volume change rate ranking (10:00) - TWOSTONE&Sons, immunobiology etc. ranked in.
In the volume change rate ranking, you can understand the interest of market participants such as trends in speculation by comparing the average volume of the last 5 days with the volume on the delivery day. ■ Volume Change Rate Top [As of October 16, 10:32] (Comparison with the average volume of the last 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <1486> Listed US bonds 7638 24389.04 9362.2% 0.0012% <4570> Immunobiology 1
No Data
No Data